Prosecution Insights
Last updated: November 20, 2026
Application No. 18/405,409

WELLBORE FLUIDS INCLUDING SHALE INHIBITORS, AND RELATED METHODS

Final Rejection §102§103
Filed
Jan 05, 2024
Examiner
RUNYAN, SILVANA C
Art Unit
1616
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Schlumberger Technology Corporation
OA Round
2 (Final)
83%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
890 granted / 1077 resolved
+22.6% vs TC avg
Strong +17% interview lift
Without
With
+16.9%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 2m
Avg Prosecution
56 currently pending
Career history
1155
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
44.6%
+4.6% vs TC avg
§102
26.0%
-14.0% vs TC avg
§112
19.8%
-20.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1077 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments, filed on 09/10/2026, with respect to objection to specification, drawing, and claim 10 have been fully considered and are persuasive. The objection above, have been withdrawn. Applicant’s arguments with respect to Claims 8-11, and 13 rejected under 35 U.S.C. 102(a) (1)) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Merli et al. (US2013/0281326 A1), Claims 8-11, and 13 rejected under 35 U.S.C. 102(a) (1)) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Chamberlain et al. (US 2002/0155956), and Claims 8-11, and 13 rejected under 35 U.S.C. 103 as being unpatentable over Merli and further in view of May et al. (US 2021/0102108 A1) have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. In response to applicant’s argument that there is no teaching, suggestion, or motivation to combine the references, the examiner recognizes that obviousness may be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See In re Fine, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988), In re Jones, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992), and KSR International Co. v. Teleflex, Inc., 550 U.S. 398, 82 USPQ2d 1385 (2007). The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 8-10,and 22 are rejected under 35 U.S.C. 103 as being unpatentable over Wagle et al. (US 2023/0323183 A1) (“Wagle” herein) Claim 8. Wagle discloses a wellbore fluid, comprising: an aqueous base fluid; and a solid shale inhibitor dissolved in the aqueous base fluid as a dry solid, the solid shale inhibitor consisting essentially of a hexamethylenediamine hydrochloride. [0005,0010-0011, 0014-0029] Wagle does not explicitly disclose the hexamethylenediamine hydrochloride having a purity greater than 90 percent. Wage recites ¶ [0029] In one or more embodiments, after the ethylene ammonium salt has been produced, the product may be purified by any suitable means, such as by freeze-drying, recrystallization, and/or filtration steps. Such steps are known by those skilled in the art. Accordingly, it would have been within a person of skill in the art and the before the effective filling date of the claimed invention and the examiner takes an Official Notice that a compound, as a solid product through at least a re-crystallization process, with the highest purity, such as the shale inhibitor of Wagle, would be preferred in order to prevent possible unexpected reaction within the wellbore fluid composition or in the wellbore. Pure materials are novel vis-à-vis less pure or impure materials because there is a difference between pure and impure materials. Therefore, the issue is whether claims to a pure material are nonobvious over the prior art. In re Bergstrom, 427 F.2d 1394, 166 USPQ 256 (CCPA 1970). Purer forms of known products may be patentable, but the mere purity of a product, by itself, does not render the product nonobvious. Factors to be considered in determining whether a purified form of an old product is obvious over the prior art include whether the claimed chemical compound or composition has the same utility as closely related materials in the prior art, and whether the prior art suggests the particular form or structure of the claimed material or suitable methods of obtaining that form or structure. In re Cofer, 354 F.2d 664, 148 USPQ 268 (CCPA 1966) (Claims to the free-flowing crystalline form of a compound were held nonobvious over references disclosing the viscous liquid form of the same compound because the prior art of record did not suggest the claimed compound in crystalline form or how to obtain such crystals.). However, in the case of product-by-process claims, if a first prior art process is improved to enhance the purity of the product produced by the process, and if the purified product has no structural or functional difference from the products produced by other prior art processes, then the improvement in the first process that improves the purity of the product does not give rise to patentability. See Purdue Pharma v. Epic Pharma, 811 F.3d 1345, 117 USPQ2d 1733 (Fed. Cir. 2016). See also MPEP § 2113. See also Ex parte Stern, 13 USPQ2d 1379 (Bd. Pat. App. & Inter. 1987) (Claims to interleukin-2 (a protein with a molecular weight of over 12,000) purified to homogeneity were held unpatentable over references which recognized the desirability of purifying interleukin-2 to homogeneity in a view of a reference which taught a method of purifying proteins having molecular weights in excess of 12,000 to homogeneity wherein the prior art method was similar to the method disclosed by appellant for purifying interleukin-2). Claim 9. Wagle discloses the wellbore fluid of claim 8, further comprising at least one viscosifier. [0032] Claim 10. Wagle discloses the wellbore fluid of claim 8, wherein the solid shale inhibitor constitutes from 0.5 volume percent to 5.0 volume percent of the wellbore fluid.[0030] Claim 22. Wagle discloses the wellbore fluid of claim 8, wherein: the solid shale inhibitor has a purity greater than 98 percent; [0014-0029 and claim 1] the solid shale inhibitor is free of 1,2-diaminocyclohexane and bis-hexamethylene triamine; (i.e. other compounds of Formula III and IV) [0011] and the solid shale inhibitor constitutes from 0.5 volume percent to 2 volume percent of the wellbore fluid. [0029-0030] Since Wagle discloses the same wellbore fluid composition comprising water and a hexamethylenediamine hydrochloride , it would be a wellbore fluid with a pH within a range of from 8 to 10. "Products of identical chemical composition cannot have mutually exclusive properties”. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant disc loses and /or claims are necessarily present. See MPEP 2112.01 (I), In re Best, 562 F2d at 1255, 195 USPQ at 433, Titanium Metals Corp v Banner, 778 F2d 775, 227 USPQ 773 (Fed Cir 1985) , In re Ludtke, 441 F2d 660, 169 USPQ 563 (CCPA 1971) and Northam Wareen Corp v DF Newfield Co, 7 F Supp 773, 22 USPQ 313 (EDNY1934). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SILVANA C RUNYAN whose telephone number is (571)270-5415. The examiner can normally be reached M-F 7:30-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sue Lui can be reached at 571-272-5539. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SILVANA C RUNYAN/Primary Examiner, Art Unit 1616 11/04/2026
Read full office action

Prosecution Timeline

Jan 05, 2024
Application Filed
Jun 11, 2026
Non-Final Rejection mailed — §102, §103
Jun 12, 2026
Interview Requested
Jun 18, 2026
Examiner Interview Summary
Jun 18, 2026
Applicant Interview (Telephonic)
Sep 10, 2026
Response Filed
Nov 06, 2026
Final Rejection mailed — §102, §103
Nov 06, 2026
Interview Requested

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790939
METHODS AND MATERIALS FOR MONITORING STIMULATION EFFECTIVENESS USING COATED TRACERS
2y 5m to grant Granted Nov 10, 2026
Patent 12767878
DOWNHOLE SLUDGE REMOVAL
2y 3m to grant Granted Oct 20, 2026
Patent 12760631
SYSTEM AND METHOD FOR ENHANCED OIL RECOVERY UTILIZING ALTERNATING STACKED LIQUID AND GAS SLUGS
1y 9m to grant Granted Oct 13, 2026
Patent 12753665
AROMATIC COPOLYESTER THERMOSET DOWNHOLE TOOLS
2y 0m to grant Granted Oct 06, 2026
Patent 12753685
WATERFLOODING SYSTEM AND PROCESS TO PREVENT SCALE PRECIPITATION IN OIL FIELDS
1y 4m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
83%
Grant Probability
99%
With Interview (+16.9%)
2y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1077 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month